今日的美国食品药品监督管理局。 - Suppr

Suppr

超能文献

Today's FDA.

作者信息

Slater Eve E

出版信息

N Engl J Med. 2005 Jan 20;352(3):293-7. doi: 10.1056/NEJMsb042278.

DOI:10.1056/NEJMsb042278

PMID:15659733

Abstract

摘要

相似文献

Today's FDA.

N Engl J Med. 2005 Jan 20;352(3):293-7. doi: 10.1056/NEJMsb042278.

What ails the FDA?

N Engl J Med. 2005 Mar 17;352(11):1063-6. doi: 10.1056/NEJMp058003.

Paying for drug approvals--who's using whom?

N Engl J Med. 2007 Apr 26;356(17):1697-700. doi: 10.1056/NEJMp078041. Epub 2007 Apr 13.

FDA restructures new product review centers.

Nat Biotechnol. 2002 Oct;20(10):960. doi: 10.1038/nbt1002-960a.

Drug safety reform at the FDA--pendulum swing or systematic improvement?

N Engl J Med. 2007 Apr 26;356(17):1700-2. doi: 10.1056/NEJMp078057. Epub 2007 Apr 13.

FDA not NIH can speed new drugs.

Nature. 2011 Apr 14;472(7342):169. doi: 10.1038/472169a.

Avoiding the regulatory capture of the Food and Drug Administration.

Arch Intern Med. 2007 Apr 9;167(7):732-3. doi: 10.1001/archinte.167.7.732-b.

PDUFA reauthorization--drug safety's golden moment of opportunity?

N Engl J Med. 2007 Apr 26;356(17):1703-4. doi: 10.1056/NEJMp078048. Epub 2007 Apr 13.

US Senate passes FDA Revitalization Act.

CMAJ. 2007 Jul 3;177(1):23. doi: 10.1503/cmaj.070779.

Perspectives. Approval process a moving target in FDA reform hearings.

Faulkner Grays Med Health. 1996 Feb 19;50(8):suppl 1-4.

引用本文的文献

A Grant-Based Experiment to Train Clinical Investigators: The AACR/ASCO Methods in Clinical Cancer Research Workshop.

Clin Cancer Res. 2021 Oct 15;27(20):5472-5481. doi: 10.1158/1078-0432.CCR-21-1799. Epub 2021 Jul 26.

A plea for a more epidemiological and patient-oriented pharmacovigilance.

Eur J Clin Pharmacol. 2012 Jan;68(1):11-9. doi: 10.1007/s00228-011-1096-2. Epub 2011 Jul 20.

Preemption, tort reform, and pharmaceutical claims: Part two: Has the Food and Drug Administration shown it is solely responsible for the protection of patients? Can it do so? Will it do so?

Proc (Bayl Univ Med Cent). 2008 Jan;21(1):82-92. doi: 10.1080/08998280.2008.11928368.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Today's FDA.

N Engl J Med. 2005 Jan 20;352(3):293-7. doi: 10.1056/NEJMsb042278.

What ails the FDA?

N Engl J Med. 2005 Mar 17;352(11):1063-6. doi: 10.1056/NEJMp058003.

Paying for drug approvals--who's using whom?

N Engl J Med. 2007 Apr 26;356(17):1697-700. doi: 10.1056/NEJMp078041. Epub 2007 Apr 13.

FDA restructures new product review centers.

Nat Biotechnol. 2002 Oct;20(10):960. doi: 10.1038/nbt1002-960a.

Drug safety reform at the FDA--pendulum swing or systematic improvement?

N Engl J Med. 2007 Apr 26;356(17):1700-2. doi: 10.1056/NEJMp078057. Epub 2007 Apr 13.

FDA not NIH can speed new drugs.

Nature. 2011 Apr 14;472(7342):169. doi: 10.1038/472169a.

Avoiding the regulatory capture of the Food and Drug Administration.

Arch Intern Med. 2007 Apr 9;167(7):732-3. doi: 10.1001/archinte.167.7.732-b.

PDUFA reauthorization--drug safety's golden moment of opportunity?

N Engl J Med. 2007 Apr 26;356(17):1703-4. doi: 10.1056/NEJMp078048. Epub 2007 Apr 13.

US Senate passes FDA Revitalization Act.

CMAJ. 2007 Jul 3;177(1):23. doi: 10.1503/cmaj.070779.

Perspectives. Approval process a moving target in FDA reform hearings.

Faulkner Grays Med Health. 1996 Feb 19;50(8):suppl 1-4.

引用本文的文献

A Grant-Based Experiment to Train Clinical Investigators: The AACR/ASCO Methods in Clinical Cancer Research Workshop.

Clin Cancer Res. 2021 Oct 15;27(20):5472-5481. doi: 10.1158/1078-0432.CCR-21-1799. Epub 2021 Jul 26.

A plea for a more epidemiological and patient-oriented pharmacovigilance.

Eur J Clin Pharmacol. 2012 Jan;68(1):11-9. doi: 10.1007/s00228-011-1096-2. Epub 2011 Jul 20.

Preemption, tort reform, and pharmaceutical claims: Part two: Has the Food and Drug Administration shown it is solely responsible for the protection of patients? Can it do so? Will it do so?

Proc (Bayl Univ Med Cent). 2008 Jan;21(1):82-92. doi: 10.1080/08998280.2008.11928368.